About the Article
Article Files
[This article belongs to Volume - 71, Issue - 5]
Published on : 2026-05-22 21:25:51
Article Code: AMJ-22-05-2026-12377
Title : Doubling of Distant-Stage Cancer Survival in the United States, Mid-1990s to 2015–2021: A Surveillance-Based Case for the Therapeutics-Led Era
Author(s) : Sibah Bin Ali
Abstract :
The dominant narrative of U.S. cancer surveillance has long been a story of prevention: smoking fell, and the death rate followed. That story is true but no longer complete. Drawing on the American Cancer Society’s 2026 surveillance estimates and the underlying SEER and National Center for Health Statistics data, we argue that the United States has crossed a qualitative threshold. Five-year relative survival for all cancers combined has reached 70%, but the headline understates what happened beneath it: the largest proportional gains now belong to the cancers once written off. Distant-stage (metastatic) survival for all sites doubled, from 17% to 35%, between the mid-1990s and 2015–2021; metastatic lung-cancer survival rose roughly five-fold, from 2% to 10%; and myeloma survival nearly doubled, from 32% to 62%. We contend that cancer control has entered a therapeutics-led phase, in which molecular and immunologic treatment—not screening alone—increasingly drives population mortality. This reframing carries a sharp corollary: gains concentrated in late-stage disease are uniquely dependent on continuous access to expensive, recently approved drugs, and are therefore uniquely vulnerable to disruptions in research funding and insurance coverage.